Need a Covid jab? If you’re in Thailand, you’ll have a new option. The Food and Drug Administration has approved the protein-based Covovax vaccine manufactured by Novavax for active immunisation against Covid-19.
The FDA granted the vaccine emergency-use authorisation for individuals 18 years of age and older last Friday, according to a press release from Novavax. The vaccine — known officially as NVX-CoV2373 — is manufactured and marketed under the brand name Covovax.
The FDA’s decision was based on the preclinical, manufacturing and clinical trial data submitted for review. US-based biotechnology company Novavax has conducted two pivotal Phase 3 clinical trials.
One trial, PREVENT-19, included 30,000 participants aged 18 years and older in the US and Mexico and the results were published in the New England Journal of Medicine. Another trial was conducted with almost…
